All In Biotech

Drug Trial Radar · NCT06479720

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder

Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 16, 2022

Primary completion

Jun 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Mackay Memorial HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder

Conditions

  • Effect of Drug
  • Urinary Bladder, Overactive

Interventions

  • Combined pharmacotherapy with Solifenacin and MirabegronDrug

    Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.

  • Solifenacin with vaginal estrogen creamDrug

    Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).

  • Mirabegron with vaginal estrogen creamDrug

    Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Short form of Urinary Distress Inventory (UDI-6)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
  2. Short form of Incontinence Impact Questionnaire (IIQ-7)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
  3. Overactive Bladder Symptom Score (OABSS)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mackay Memorial Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.